Get the Stockscreener App
2.38
12.26%
0.26
After Hours:
2.39
0.01
+0.42%
Vor Biopharma Inc stock is traded at $2.38, with a volume of 11.98M.
It is up +12.26% in the last 24 hours and up +1,054% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$2.12
Open:
$2.15
24h Volume:
11.98M
Relative Volume:
0.74
Market Cap:
$297.40M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-1.4512
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
+3.03%
1M Performance:
+1,054%
6M Performance:
+78.95%
1Y Performance:
+138.81%
1-Day Range:
$2.1493
$2.65
1-Week Range:
$1.92
$2.84
52-Week Range:
$0.1311
$3.29
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.38 | 317.40M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySmart Money Signals - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Vor Biopharma Soars 19.1% on Analyst Upgrade - AInvest
Vor Biopharma Stock Skyrockets: What’s Next? - StocksToTrade
Vor Biopharma shares surge 28.01% intraday after licensing telitacicept for autoimmune diseases and raising $1.75B in private funding. - AInvest
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by HC Wainwright - Defense World
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Massive CEO Stock Grant: Vor Bio Awards 83M Shares to New Chief Executive at $0.89 - Stock Titan
Vor Biopharma (NYSE:VOR) Rating Increased to Buy at HC Wainwright - Defense World
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market - Benzinga
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwri - GuruFocus
Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal - Investing.com
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwright & Co. | VOR Stock News - GuruFocus
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why - Yahoo Finance
VOR SEC FilingsVor Biopharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vor Biopharma's Mysterious 10% Spike: What Drives a Stock Without Technical Triggers? - AInvest
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept - BioWorld MedTech
Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact - insights.citeline.com
PureTech's Vor Bio Lands $4B Autoimmune Drug Deal, Names New CEO, Raises $175M - Stock Titan
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - Yahoo Finance
Vor Biopharma Stock Rises 1.72% Amid Mixed Analyst Forecasts - AInvest
Short Interest in Vor Biopharma Inc. (NYSE:VOR) Increases By 51.8% - Defense World
Vor Biopharma Inc (VOR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Market Insights: Triller Group Inc (ILLR)’s Notable Gain of 1.91, Closing at 0.69 - DWinneX
Vor Biopharma Inc (VOR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Data-Based Insights About Vor Biopharma Inc (VOR) - Stocksregister
Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Hold” by Analysts - Defense World
Northern Trust Corp Acquires 44,252 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Cambridge biotech company researching blood cancers to close, lay off 155 - Yahoo Finance
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma draws downgrades on strategic review - MSN
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options By Investing.com - Investing.com South Africa
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Approves Share Increase at Annual Meeting - TipRanks
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):